965 related articles for article (PubMed ID: 34535562)
1. Selective Acetyl-CoA Carboxylase 1 Inhibitor Improves Hepatic Steatosis and Hepatic Fibrosis in a Preclinical Nonalcoholic Steatohepatitis Model.
Tamura YO; Sugama J; Iwasaki S; Sasaki M; Yasuno H; Aoyama K; Watanabe M; Erion DM; Yashiro H
J Pharmacol Exp Ther; 2021 Nov; 379(3):280-289. PubMed ID: 34535562
[TBL] [Abstract][Full Text] [Related]
2. Acetyl-CoA carboxylase 1 and 2 inhibition ameliorates steatosis and hepatic fibrosis in a MC4R knockout murine model of nonalcoholic steatohepatitis.
Matsumoto M; Yashiro H; Ogino H; Aoyama K; Nambu T; Nakamura S; Nishida M; Wang X; Erion DM; Kaneko M
PLoS One; 2020; 15(1):e0228212. PubMed ID: 31990961
[TBL] [Abstract][Full Text] [Related]
3. Acetyl-CoA Carboxylase Inhibition Improves Multiple Dimensions of NASH Pathogenesis in Model Systems.
Ross TT; Crowley C; Kelly KL; Rinaldi A; Beebe DA; Lech MP; Martinez RV; Carvajal-Gonzalez S; Boucher M; Hirenallur-Shanthappa D; Morin J; Opsahl AC; Vargas SR; Bence KK; Pfefferkorn JA; Esler WP
Cell Mol Gastroenterol Hepatol; 2020; 10(4):829-851. PubMed ID: 32526482
[TBL] [Abstract][Full Text] [Related]
4. Acetyl-CoA carboxylase inhibition disrupts metabolic reprogramming during hepatic stellate cell activation.
Bates J; Vijayakumar A; Ghoshal S; Marchand B; Yi S; Kornyeyev D; Zagorska A; Hollenback D; Walker K; Liu K; Pendem S; Newstrom D; Brockett R; Mikaelian I; Kusam S; Ramirez R; Lopez D; Li L; Fuchs BC; Breckenridge DG
J Hepatol; 2020 Oct; 73(4):896-905. PubMed ID: 32376414
[TBL] [Abstract][Full Text] [Related]
5. GS-0976 (Firsocostat): an investigational liver-directed acetyl-CoA carboxylase (ACC) inhibitor for the treatment of non-alcoholic steatohepatitis (NASH).
Alkhouri N; Lawitz E; Noureddin M; DeFronzo R; Shulman GI
Expert Opin Investig Drugs; 2020 Feb; 29(2):135-141. PubMed ID: 31519114
[No Abstract] [Full Text] [Related]
6. WZ66, a novel acetyl-CoA carboxylase inhibitor, alleviates nonalcoholic steatohepatitis (NASH) in mice.
Gao YS; Qian MY; Wei QQ; Duan XB; Wang SL; Hu HY; Liu J; Pan CY; Zhang SQ; Qi LW; Zhou JP; Zhang HB; Wang LR
Acta Pharmacol Sin; 2020 Mar; 41(3):336-347. PubMed ID: 31645659
[TBL] [Abstract][Full Text] [Related]
7. Reversal of diet-induced hepatic steatosis and hepatic insulin resistance by antisense oligonucleotide inhibitors of acetyl-CoA carboxylases 1 and 2.
Savage DB; Choi CS; Samuel VT; Liu ZX; Zhang D; Wang A; Zhang XM; Cline GW; Yu XX; Geisler JG; Bhanot S; Monia BP; Shulman GI
J Clin Invest; 2006 Mar; 116(3):817-24. PubMed ID: 16485039
[TBL] [Abstract][Full Text] [Related]
8. Acetyl-CoA Carboxylase Inhibition Reverses NAFLD and Hepatic Insulin Resistance but Promotes Hypertriglyceridemia in Rodents.
Goedeke L; Bates J; Vatner DF; Perry RJ; Wang T; Ramirez R; Li L; Ellis MW; Zhang D; Wong KE; Beysen C; Cline GW; Ray AS; Shulman GI
Hepatology; 2018 Dec; 68(6):2197-2211. PubMed ID: 29790582
[TBL] [Abstract][Full Text] [Related]
9. Acetyl-CoA Carboxylase Inhibitor GS-0976 for 12 Weeks Reduces Hepatic De Novo Lipogenesis and Steatosis in Patients With Nonalcoholic Steatohepatitis.
Lawitz EJ; Coste A; Poordad F; Alkhouri N; Loo N; McColgan BJ; Tarrant JM; Nguyen T; Han L; Chung C; Ray AS; McHutchison JG; Subramanian GM; Myers RP; Middleton MS; Sirlin C; Loomba R; Nyangau E; Fitch M; Li K; Hellerstein M
Clin Gastroenterol Hepatol; 2018 Dec; 16(12):1983-1991.e3. PubMed ID: 29705265
[TBL] [Abstract][Full Text] [Related]
10. Acetyl CoA Carboxylase Inhibition Reduces Hepatic Steatosis but Elevates Plasma Triglycerides in Mice and Humans: A Bedside to Bench Investigation.
Kim CW; Addy C; Kusunoki J; Anderson NN; Deja S; Fu X; Burgess SC; Li C; Ruddy M; Chakravarthy M; Previs S; Milstein S; Fitzgerald K; Kelley DE; Horton JD
Cell Metab; 2017 Aug; 26(2):394-406.e6. PubMed ID: 28768177
[TBL] [Abstract][Full Text] [Related]
11. GS-0976 Reduces Hepatic Steatosis and Fibrosis Markers in Patients With Nonalcoholic Fatty Liver Disease.
Loomba R; Kayali Z; Noureddin M; Ruane P; Lawitz EJ; Bennett M; Wang L; Harting E; Tarrant JM; McColgan BJ; Chung C; Ray AS; Subramanian GM; Myers RP; Middleton MS; Lai M; Charlton M; Harrison SA
Gastroenterology; 2018 Nov; 155(5):1463-1473.e6. PubMed ID: 30059671
[TBL] [Abstract][Full Text] [Related]
12. Pan-caspase inhibitor VX-166 reduces fibrosis in an animal model of nonalcoholic steatohepatitis.
Witek RP; Stone WC; Karaca FG; Syn WK; Pereira TA; Agboola KM; Omenetti A; Jung Y; Teaberry V; Choi SS; Guy CD; Pollard J; Charlton P; Diehl AM
Hepatology; 2009 Nov; 50(5):1421-30. PubMed ID: 19676126
[TBL] [Abstract][Full Text] [Related]
13. Combinations of an acetyl CoA carboxylase inhibitor with hepatic lipid modulating agents do not augment antifibrotic efficacy in preclinical models of NASH and fibrosis.
Vijayakumar A; Okesli-Armlovich A; Wang T; Olson I; Seung M; Kusam S; Hollenback D; Mahadevan S; Marchand B; Toteva M; Breckenridge DG; Trevaskis JL; Bates J
Hepatol Commun; 2022 Sep; 6(9):2298-2309. PubMed ID: 35735253
[TBL] [Abstract][Full Text] [Related]
14. Investigating dual inhibition of ACC and CD36 for the treatment of nonalcoholic fatty liver disease in mice.
Devereux CJ; Bayliss J; Keenan SN; Montgomery MK; Watt MJ
Am J Physiol Endocrinol Metab; 2023 Feb; 324(2):E187-E198. PubMed ID: 36629823
[TBL] [Abstract][Full Text] [Related]
15. Acetyl-CoA carboxylase inhibitors in non-alcoholic steatohepatitis: Is there a benefit?
Neokosmidis G; Cholongitas E; Tziomalos K
World J Gastroenterol; 2021 Oct; 27(39):6522-6526. PubMed ID: 34754150
[TBL] [Abstract][Full Text] [Related]
16. Ezetimibe prevents the development of non‑alcoholic fatty liver disease induced by high‑fat diet in C57BL/6J mice.
Wang X; Ren Q; Wu T; Guo Y; Liang Y; Liu S
Mol Med Rep; 2014 Dec; 10(6):2917-23. PubMed ID: 25310357
[TBL] [Abstract][Full Text] [Related]
17. Vitamin B5 and N-Acetylcysteine in Nonalcoholic Steatohepatitis: A Preclinical Study in a Dietary Mouse Model.
Machado MV; Kruger L; Jewell ML; Michelotti GA; Pereira Tde A; Xie G; Moylan CA; Diehl AM
Dig Dis Sci; 2016 Jan; 61(1):137-48. PubMed ID: 26403427
[TBL] [Abstract][Full Text] [Related]
18. Hepatic de novo lipogenesis is present in liver-specific ACC1-deficient mice.
Harada N; Oda Z; Hara Y; Fujinami K; Okawa M; Ohbuchi K; Yonemoto M; Ikeda Y; Ohwaki K; Aragane K; Tamai Y; Kusunoki J
Mol Cell Biol; 2007 Mar; 27(5):1881-8. PubMed ID: 17210641
[TBL] [Abstract][Full Text] [Related]
19. Psoralea corylifolia L. extract ameliorates nonalcoholic fatty liver disease in free-fatty-acid-incubated HEPG2 cells and in high-fat diet-fed mice.
Hong Y; Choi SI; Hong E; Kim GH
J Food Sci; 2020 Jul; 85(7):2216-2226. PubMed ID: 32579753
[TBL] [Abstract][Full Text] [Related]
20. Inhibition of Acetyl-CoA Carboxylase by Phosphorylation or the Inhibitor ND-654 Suppresses Lipogenesis and Hepatocellular Carcinoma.
Lally JSV; Ghoshal S; DePeralta DK; Moaven O; Wei L; Masia R; Erstad DJ; Fujiwara N; Leong V; Houde VP; Anagnostopoulos AE; Wang A; Broadfield LA; Ford RJ; Foster RA; Bates J; Sun H; Wang T; Liu H; Ray AS; Saha AK; Greenwood J; Bhat S; Harriman G; Miao W; Rocnik JL; Westlin WF; Muti P; Tsakiridis T; Harwood HJ; Kapeller R; Hoshida Y; Tanabe KK; Steinberg GR; Fuchs BC
Cell Metab; 2019 Jan; 29(1):174-182.e5. PubMed ID: 30244972
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
